The Zhitong Finance App learned that Yiming Onko-B (01541) rose more than 6% at the end of the session. As of press release, it had risen 5.47% to HK$3.375, with a turnover of HK$722,600.

According to the news, after receiving IND approval from the US FDA for systemic lupus erythematosus indications on August 21 this year, the bispecific molecule amulefp α (IMM0306), which targets CD47 and CD20 independently developed by Yiming Angke, once again ushered in a milestone. On September 23, Yiming Angke announced the latest results of the phase IB/IIa clinical study of amulirafusp alpha (amulirafusp alfa, IMM0306) combined with lenalidomide (Lenalidomide) in the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma, which was independently developed by the company.

It is worth mentioning that with the disclosure of IMM0306's major data on the two indications, Yiming Angke's certainty in differentiating original research and innovation has been further confirmed. Currently, the drug has been approved for clinical trials by the US FDA. In addition to FL and MZL indications, the drug is also efficiently promoting clinical development in various fields including FL, SLE, IgG4-RD, NMOSD, membranous nephropathy, and PSS. In the future, when this potential FIC/BIC product is successfully approved for listing, it is expected that it will become a key part of Yiming Enke's continuous increase in the company's profits, further opening up more room for the company's valuation imagination.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.